IL303154A - Factor against human epidermal growth factor receptor 2 - Google Patents

Factor against human epidermal growth factor receptor 2

Info

Publication number
IL303154A
IL303154A IL303154A IL30315423A IL303154A IL 303154 A IL303154 A IL 303154A IL 303154 A IL303154 A IL 303154A IL 30315423 A IL30315423 A IL 30315423A IL 303154 A IL303154 A IL 303154A
Authority
IL
Israel
Prior art keywords
amino acid
antibody
seq
acid sequence
antigen
Prior art date
Application number
IL303154A
Other languages
English (en)
Hebrew (he)
Inventor
Yukinari Kato
Mika Kaneko
Daisuke Nakayama
Masayuki KUROGI
Original Assignee
Ono Pharmaceutical Co
Univ Tohoku
Yukinari Kato
Mika Kaneko
Daisuke Nakayama
Masayuki KUROGI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Univ Tohoku, Yukinari Kato, Mika Kaneko, Daisuke Nakayama, Masayuki KUROGI filed Critical Ono Pharmaceutical Co
Publication of IL303154A publication Critical patent/IL303154A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL303154A 2020-11-30 2021-11-29 Factor against human epidermal growth factor receptor 2 IL303154A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020198044 2020-11-30
JP2021110912 2021-07-02
PCT/JP2021/043538 WO2022114163A1 (ja) 2020-11-30 2021-11-29 Ｈｅｒ２標的化剤

Publications (1)

Publication Number Publication Date
IL303154A true IL303154A (en) 2023-07-01

Family

ID=81754499

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303154A IL303154A (en) 2020-11-30 2021-11-29 Factor against human epidermal growth factor receptor 2

Country Status (10)

Country Link
US (2) US20240002531A1 (https=)
EP (1) EP4253420A4 (https=)
JP (2) JP7393774B2 (https=)
KR (1) KR20230114747A (https=)
AU (1) AU2021387127A1 (https=)
CA (1) CA3199473A1 (https=)
IL (1) IL303154A (https=)
MX (1) MX2023005864A (https=)
TW (2) TW202546008A (https=)
WO (1) WO2022114163A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3247010A1 (en) 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
EP4504914A4 (en) * 2022-04-08 2026-04-29 Fate Therapeutics Inc Cells having solid tumor targeting backbone and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
PT2330131E (pt) 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US11851479B2 (en) * 2018-06-18 2023-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis
CA3247010A1 (en) * 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING

Also Published As

Publication number Publication date
MX2023005864A (es) 2023-06-05
EP4253420A1 (en) 2023-10-04
TW202546008A (zh) 2025-12-01
WO2022114163A1 (ja) 2022-06-02
KR20230114747A (ko) 2023-08-01
US11981747B1 (en) 2024-05-14
US20240002531A1 (en) 2024-01-04
TW202229359A (zh) 2022-08-01
JP7393774B2 (ja) 2023-12-07
AU2021387127A1 (en) 2023-06-22
JP2024020436A (ja) 2024-02-14
JPWO2022114163A1 (https=) 2022-06-02
CA3199473A1 (en) 2022-06-02
EP4253420A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
US12129296B2 (en) Anti-human claudin 18.2 monoclonal antibody and application thereof
RU2737882C2 (ru) Биспецифические антигенсвязывающие конструкции против her2
JP7138766B2 (ja) ヒトｈｅｒ２に結合する抗体、その製造方法および治療薬
CN106999576B (zh) 癌细胞特异性抗体、抗癌剂、及癌症的检查方法
WO2016171242A1 (ja) Ｅｐｈａ２の検出
US11981747B1 (en) HER2 targeting agent
US20230365676A1 (en) Cd33 antibodies
CN115505043A (zh) 特异性结合糖基化ceacam5的抗体
EP3282014B1 (en) Cancer cell-specific anti-podocalyxin antibody and method for producing same
KR102249981B1 (ko) 단클론성 항-gpc-1 항체 및 이의 용도
WO2017154868A1 (ja) 抗ｔｍｅｍ－１８０抗体、抗がん剤、及びがんの検査方法
CA3113306A1 (en) Her2-binding tetrameric polypeptides
JP2019050737A (ja) Ｃｄ４４陽性ｔｍｅｍ−１８０陽性のがん細胞由来微粒子、これを用いた抗ｔｍｅｍ−１８０抗体療法が有効ながん患者の選別方法、選別された患者に対する抗ｔｍｅｍ−１８０抗体を含む抗がん剤、および前記方法に用いるキット
TW201840588A (zh) 抗ｇｐｒ２０抗體
US20210395396A1 (en) Her2-binding tetrameric polypeptides
CN116615239A (zh) Her2靶向剂
HK40091222A (zh) Her2靶向剂
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
Ludwig DESIGN OF MULTI-PARATOPIC ANTIBODIES FOR RECEPTOR DOWNREGULATION AND A GLYCO-ENGINEERING PLATFORM FOR THEAPEUTIC ANTIBODIES
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
EP4493595A1 (en) Antibodies against lypd3
WO2025117639A9 (en) Antibodies and methods for ptk7 detection
HK40095347A (zh) 上皮钙黏素特异性抗体
HK40040192A (en) Antibody binding to human her2 and preparation method and use thereof
HK40051469A (en) Her2-binding tetrameric polypeptides